Valuation: Spyre Therapeutics, Inc.

Market Cap 9.25B 8B 7.47B 6.85B 12.89B 880B 13.1B 87.67B 34.41B 441B 34.74B 33.98B 1,459B P/E 2026 *
-36.3x
P/E 2027 * -29.8x
Enterprise Value 8.77B 7.59B 7.09B 6.5B 12.23B 835B 12.42B 83.13B 32.63B 418B 32.94B 32.22B 1,383B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
93.32%
Yield 2026 *
-
Yield 2027 * -
1 day+1.44%
1 week+6.69%
Current month+6.69%
1 month+9.97%
3 months+39.80%
6 months+198.72%
Current year+220.24%
1 week 92.71
Extreme 92.71
108.14
1 month 92.37
Extreme 92.37
108.14
Current year 28
Extreme 28
108.14
1 year 14.5
Extreme 14.505
108.14
3 years 8.43
Extreme 8.43
108.14
5 years 2.66
Extreme 2.66
212.5
10 years 2.66
Extreme 2.66
300
Manager TitleAgeSince
Chief Executive Officer 36 2023-11-26
Director of Finance/CFO 49 2023-08-31
Chief Tech/Sci/R&D Officer - 2023-11-26
Director TitleAgeSince
Director/Board Member 36 2023-11-26
Director/Board Member 39 2023-06-21
Director/Board Member 36 2023-06-21
Date Insider Type Main position Quantity % Market Cap.
8/3/26 Fiscal year

Chief Financial Officer

22,500 0.0259%
8/3/26 Sell

Chief Executive Officer

-15,000 0.0173%
7/1/26 Sell

Chief Executive Officer

-15,000 0.0173%
Change 5-day change 1-year change 3-year change Capi.($)
+1.44%+6.69%+592.02%+810.28% 9.25B
+8.49%+20.55%+70.77%+110.32% 68.12B
+1.25%+2.44%+34.27%+70.43% 55.18B
-1.09%+32.96%+19.67%+494.56% 28.63B
+10.83%+18.38%+56.20%+6.03% 23.99B
+2.72%+3.41%-16.11%-7.96% 23.53B
+6.50%+7.56%+44.65%-21.73% 18.45B
+6.20%+11.51%+33.87%+693.38% 16.44B
-3.88%+16.98%+199.30%+359.77% 15.83B
+3.58%+1.96%+43.35%+163.76% 13.4B
Average +3.60%+11.18%+107.80%+267.89% 27.28B
Weighted average by Cap. +4.26%+12.88%+69.05%+190.24%

Financials

2026 *2027 *
Net sales - -
Net income -258M -223M -209M -191M -360M -24.57B -366M -2.45B -961M -12.32B -970M -948M -40.72B -327M -283M -264M -242M -455M -31.1B -463M -3.1B -1.22B -15.59B -1.23B -1.2B -51.53B
Net Debt -478M -414M -386M -355M -667M -45.53B -677M -4.53B -1.78B -22.82B -1.8B -1.76B -75.45B -518M -448M -418M -384M -721M -49.26B -733M -4.9B -1.93B -24.69B -1.94B -1.9B -81.62B
Logo Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, specializing in long-acting antibodies and antibody combinations for inflammatory bowel disease (IBD) and rheumatic diseases. The Company's pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. It is advancing a pipeline of monoclonal antibodies (mAbs) for the treatment of IBD and other immune-mediated diseases. The Company's pipeline includes its SKYLINE Phase II platform trial evaluating SPY001, SPY002, SPY003, and pairwise combinations thereof in subjects with moderately to severely active UC and its SKYWAY basket trial evaluating SPY072 in three rheumatic diseases: rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). SPY001 is a highly potent, highly selective, and humanized monoclonal immunoglobulin G1 investigational antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD (UC and CD).
Employees
125
Date Price Change Volume
26-08-07 US$104.91 +1.44% 526,596
26-08-06 US$103.42 -0.89% 454,482
26-08-05 US$104.35 -0.56% 1,037,497
26-08-04 US$104.94 +10.54% 831,997
26-08-03 US$94.93 -3.46% 898,396
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
104.91USD
Average target price
120.07USD
Spread / Average Target
+14.45%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SYRE Stock